Board Appointment

Poolbeg Pharma

24/05/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230524:nRSX4071Aa&default-theme=true

RNS Number : 4071A  Poolbeg Pharma PLC  24 May 2023

Poolbeg Pharma plc

 

Board Appointment

 

24 May 2023 - Poolbeg Pharma (http://www.poolbegpharma.com/)  (AIM: POLB,
OTCQB: POLBF, 'Poolbeg' or the 'Company'), a leading biopharmaceutical
company focusing on infectious and prevalent diseases with a high unmet
medical need, announces the appointment of Brendan Buckley as an Independent
Non-Executive Director of the Company with immediate effect. Brendan will also
replace Cathal Friel as a member of the Remuneration Committee.

 

Professor Buckley is the former Chief Medical Officer of ICON plc, a medical
graduate of University College Cork and a doctoral graduate in Biochemistry
in the Faculty of Medicine at Oxford University. Prof Buckley has advised
Poolbeg since inception and has deep experience in metabolic diseases
including over 40 years' experience in clinical practice as a Consultant
Physician in endocrinology, diabetes and in academic clinical pharmacology.
Brendan was a member of the Board of Directors of the Irish Medicines Board
(now the Health Products Regulatory Authority), chairing its statutory
Advisory Committee for Human Medicines. He was also a member of the European
Medicines Agency Committee for Orphan Medicinal Products (COMP) and of the
European Medicines Agency Scientific Advisory Committee on diabetes and
metabolism. Brendan has published over 150 scientific papers, mainly on
metabolic disease, as well as the recent key opinion-leading book
'Re-Engineering Clinical Trials'.

 

Jeremy Skillington, PhD, CEO of Poolbeg Pharma, said: "We are delighted to
have Brendan join the Board of Directors. His significant contribution to
Poolbeg during his role as a member of the Scientific Advisory Board, and his
considerable industry experience will be of tremendous benefit as we continue
to pursue our goal of becoming a one-stop-shop for pharma and biotechs seeking
products to in-license."

 

Brendan Buckley, Non-Executive Director of Poolbeg Pharma, said:" I am
honoured to be joining the Board at this exciting time of the Company's
development. Poolbeg has a unique model and pipeline and I look forward to
working alongside such a strong Management Team targeting a number of growing
markets."

 

Regulatory Disclosures

 

The following disclosures are required under Schedule Two, paragraph (g) of
the AIM Rules for Companies:

 

Mr Brendan Mary Buckley, aged 73, has held the following directorships and/or
partnerships in the past five years:

 

Current directorships:

 

·      hVIVO plc

·      FIGHTING BLINDNESS

·      DS BIOPHARMA LIMITED

·      Afimmune Limited

·      Open Orphan DAC

·      Imutex Ltd

 

Past directorships:

 

·      BREAKTHROUGH CANCER RESEARCH

·      Alliance for Clinical Research Excellence and Safety Inc.

 

Mr Buckley has a beneficial interest in 2,631,474 ordinary shares of the
Company representing approximately 0.5 per cent. of the total voting rights.

 

 

- Ends -

 

Enquiries

 Poolbeg Pharma Plc                                                +44 (0) 207 183 1499

 Jeremy Skillington, CEO

 Ian O'Connell, CFO

 finnCap Ltd (Nominated Adviser & Joint Broker)                    +44 (0) 207 220 0500

 Geoff Nash, Charlie Beeson, Nigel Birks, Harriet Ward (ECM)

 Singer Capital Markets (Joint Broker)                              +44 (0) 207 496 3000

 Phil Davies, Sam Butcher

 J&E Davy (Joint Broker)                                           +353 (0) 1 679 6363

 Anthony Farrell, Niall Gilchrist

 Optimum Strategic Communications                                  +44 (0) 208 078 4357

 Nick Bastin, Hana Malik, Vici Rabbetts                            poolbeg@optimumcomms.com (mailto:poolbeg@optimumcomms.com)

 

About Poolbeg Pharma

 

Poolbeg Pharma specialises in the development of innovative medicines to
address the unmet need in infectious and other prevalent diseases. Poolbeg has
a disciplined portfolio approach to mitigate risk, accelerate drug
development, and enhance investor returns. The Company simultaneously advances
multiple programmes in cost-effective clinical trials, rapidly generating
early human safety and efficacy data to enable early partnering /
out-licensing, with the funds generated reinvested in the pipeline. Poolbeg
also uses AI to interrogate human challenge trial data sets to quickly
identify new targets and drugs, and in-license near or in the clinic
medicines, leading to faster development and greater commercial appeal.

 

The Company is targeting the growing infectious disease market. In the wake of
the COVID-19 pandemic, infectious disease has become one of the fastest
growing pharma markets and is expected to exceed $250bn by 2025. Through
opportunistic identification of assets which complement Poolbeg's existing
pipeline, the Company is progressing programmes in oncology and metabolic
syndromes; adding disease areas with significant addressable markets.

 

With its initial assets from hVIVO plc (http://www.hvivo.com/)
 (formerly Open Orphan plc), an industry leading infectious disease and
human challenge trials business, Poolbeg has access to knowledge, experience,
and clinical data from over 20 years of human challenge trials. The Company is
using these insights to acquire new assets as well as reposition clinical
stage products, reducing spend and risk. Amongst its portfolio of exciting
assets, Poolbeg has a small molecule immunomodulator for severe influenza and
other acute inflammatory conditions (POLB 001) which produces a highly
significant reduction in p38 MAP kinase driven cytokines in a clinical
setting; a first-in-class, intranasally administered RNA-based immunotherapy
for respiratory virus infections (POLB 002); and a vaccine candidate for
Melioidosis (POLB 003). The Company is also developing
two Oral Delivery Programmes and is progressing
two Artificial Intelligence (AI) Programmes to add promising new assets to
its pipeline.

 

For more information, please go to www.poolbegpharma.com
(http://www.poolbegpharma.com/)  or follow us on Twitter
(https://twitter.com/PoolbegPharma)  and LinkedIn
(https://www.linkedin.com/company/poolbeg-pharma/)  @PoolbegPharma.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOABLGDUIBDDGXX